"Fenretinide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.
| Descriptor ID |
D017313
|
| MeSH Number(s) |
D02.455.326.271.665.202.495.270 D02.455.426.392.368.367.379.249.700.270 D02.455.849.131.495.270 D23.767.261.700.270
|
| Concept/Terms |
Fenretinide- Fenretinide
- N-(4-Hydroxyphenyl)-trans-Retinamide
- Fenretinimide
- N-(4-Hydroxyphenyl)retinamide
- 4-HPR
- 4-Hydroxyphenylretinamide
- 4 Hydroxyphenylretinamide
|
Below are MeSH descriptors whose meaning is more general than "Fenretinide".
Below are MeSH descriptors whose meaning is more specific than "Fenretinide".
This graph shows the total number of publications written about "Fenretinide" by people in this website by year, and whether "Fenretinide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 1 | 2 |
| 1998 | 2 | 1 | 3 |
| 1999 | 4 | 0 | 4 |
| 2000 | 3 | 1 | 4 |
| 2001 | 5 | 1 | 6 |
| 2002 | 2 | 2 | 4 |
| 2003 | 3 | 2 | 5 |
| 2004 | 6 | 0 | 6 |
| 2005 | 5 | 0 | 5 |
| 2006 | 3 | 1 | 4 |
| 2007 | 3 | 1 | 4 |
| 2008 | 2 | 0 | 2 |
| 2009 | 2 | 0 | 2 |
| 2011 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fenretinide" by people in Profiles.
-
Fenretinide metabolism in humans and mice: utilizing pharmacological modulation of its metabolic pathway to increase systemic exposure. Br J Pharmacol. 2011 Jul; 163(6):1263-75.
-
Preventive therapy for breast cancer: a consensus statement. Lancet Oncol. 2011 May; 12(5):496-503.
-
High-dose fenretinide in oral leukoplakia. Cancer Prev Res (Phila). 2009 Jan; 2(1):22-6.
-
Cyclin D1 and cancer development in laryngeal premalignancy patients. Cancer Prev Res (Phila). 2009 Jan; 2(1):14-21.
-
Involvement of Rac in fenretinide-induced apoptosis. Cancer Res. 2008 Jun 01; 68(11):4416-23.
-
Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res. 2008 Jan 01; 14(1):224-9.
-
Synthetic triterpenoids have cytotoxicity in pediatric acute lymphoblastic leukemia cell lines but cytotoxicity is independent of induced ceramide increase in MOLT-4 cells. Leukemia. 2008 Jun; 22(6):1258-62.
-
Antitumor activity of 4-(N-hydroxyphenyl)retinamide conjugated with poly(L-glutamic acid) against ovarian cancer xenografts. Gynecol Oncol. 2007 Dec; 107(3):441-9.
-
Polymeric retinoid prodrug PG-4HPR enhances the radiation response of lung cancer. Oncol Rep. 2007 Sep; 18(3):645-51.
-
Combination of 4-HPR and oral contraceptive in monkey model of chemoprevention of ovarian cancer. Front Biosci. 2007 Jan 01; 12:2260-8.